A Korean drugmaker may receive more than $800 million from U.S. drugmaker Merck under a licensing agreement for a drug developed for nonalcoholic steatohepatitis. Kenilworth,...
A U.K. drugmaker and another pharmaceutical company based in Japan have entered a deal focused on an antibody-drug conjugate for multiple tumor types that could...
A company developing a drug for a rare genetic disease that causes developmental disabilities has made a licensing deal with an Italian firm for exclusive...